Core Viewpoint - Zhen Dong Pharmaceutical (300158.SZ) announced that its associate company, Guangdong Longchuang Biopharmaceutical Co., Ltd., has achieved the primary research endpoint in the Phase III clinical trial of its project "Vaginal Lactobacillus Dual Live Bacteria Capsules" [1] Group 1: Product Development - The product is a compound preparation primarily composed of Lactobacillus gasseri and Lactobacillus rhamnosus, aimed at treating bacterial vaginosis caused by microbial imbalance [1] - Current conventional therapies for bacterial vaginosis (BV) mainly utilize antibiotics such as metronidazole, tinidazole, and clindamycin [1] Group 2: Clinical Research Findings - Long-term use of antibiotics can lead to drug resistance, making it ineffective in restoring vaginal microecology [1] - A Phase IIa clinical study indicated that the clinical cure rate of metronidazole is approximately 40% to 45% [1]

振东制药（300158）公告，参股公司龙创基药业在研项目阴道用乳杆菌二联活菌胶囊的Ⅲ期临床试验达 到主要研究终点。该胶囊用于由菌群紊乱引起的细菌性阴道病治疗，采用"以菌治菌"创新机制，具有差 异化优势。公司近期将向国家药品监督管理局药品审评中心递交上市许可申请前的沟通交流申请，积极 推进该胶囊的上市进程。 ...

证券代码：300158 证券简称：振东制药 公告编号：2025-038 二、股东股份质押基本情况 | 股东 | 是否为 | 本次质押 | 占其所 | 占公司 | 是否 | 是否为 | 质押起 | 质押到 | | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 控股股 | 数量 | 持股份 | 总股本 | 为限 | 补充 | 始日 | 期日 | 质权人 | 用途 | | | 东 | （股） | 比例 | 比例 | 售股 | 质押 | | | | | | 振东 集团 | 是 | 11,200,000 | 3.71% | 1.11% | 否 | 否 | 2025.7.29 | 办理解除 质押登记 | 中国银行股份 有限公司长治 | 自身生 产经营 | | | | | | | | | | 手续为止 | 市分行 | | | 合计 | | 11,200,000 | 3.71% | 1.11% | | | | | | | 一、股东股份解押基本情况 股东名称 是否为控 股股东 本次解押数量 （股） 占其所 持股份 ...

山西振东制药股份有限公司（以下简称"振东制药"或"公司"）参股 的广东龙创基药业有限公司（以下简称"龙创基药业"）在研项目"阴道用 乳杆菌二联活菌胶囊"的Ⅲ期临床试验达到主要研究终点。现将有关详情公 告如下： 一、药品基本情况 通用名称：阴道用乳杆菌二联活菌胶囊 英文名称：Live double combined lactobacillus capsule for vaginal use 规格：0.25g/粒。 证券代码：300158 证券简称：振东制药 公告编号：2025-039 山西振东制药股份有限公司 关于广东龙创基药业有限公司在研项目阴道用乳杆菌二联活菌 胶囊达到主要研究终点的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 三、临床试验相关情况 该Ⅲ期临床研究是一项在患者中开展的多中心、随机、双盲、安慰剂对 照的Ⅲ期临床试验。临床试验组长单位为天津医科大学总医院，牵头研究者 为薛凤霞教授，薛凤霞教授为国务院特殊津贴专家，中华医学会妇产科学分 会常委，致力于妇科肿瘤的临床与基础研究及女性生殖道感染的临床与基础 研究。 本品为复方制剂，主要成分 ...

New Stock Listings - HanGao Group listed on July 30, 2025, with an issue price of 15.43[1] - *ST Zitian and *ST Suwu are under severe abnormal fluctuations as of July 30, 2025[1] - Tianlu Convertible Bonds listed on July 30, 2025, with a risk warning[1] Market Alerts - Multiple stocks including *ST Xinchao and *ST Yuancheng are flagged for severe abnormal fluctuations on July 30, 2025[1] - New listings include companies like Xianghe Precision and Shenshui Planning, with announcements made on July 30, 2025[1] - The report includes links to detailed announcements for each stock, ensuring transparency and accessibility for investors[1] Trading Insights - The report highlights the importance of monitoring newly listed stocks for potential volatility and investment opportunities[1] - Investors are advised to review the latest announcements and risk warnings associated with these stocks to make informed decisions[1]

今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | CRO概念 | 4.00 | 猪肉 | -1.35 | | 重组蛋白 | 2.90 | 养鸡 | -1.12 | | 创新药 | 2.79 | 草甘膦 | -1.10 | | 减肥药 | 2.76 | 粮食概念 | -1.00 | | F5G概念 | 2.43 | 芬太尼 | -0.88 | | 细胞免疫治疗 | 2.42 | PEEK材料 | -0.85 | | 仿制药一致性评价 | 2.30 | 预制菜 | -0.85 | | 共封装光学(CPO) | 2.23 | 生态农业 | -0.78 | | 特钢概念 | 2.08 | C2M概念 | -0.78 | | 先进封装 | 1.91 | 人造肉 | -0.76 | 截至7月29日收盘，仿制药一致性评价概念上涨2.30%，位居概念板块涨幅第7，板块内，104股上涨， 亚太药业、九洲药业、辰欣药业等涨停，南新制药、苑东生物、海特生物等涨幅居前，分别上涨 17.01%、15.45%、15.28%。跌幅居前的有昂 ...

Market Overview - The Chinese medicine sector rose by 1.0% on July 29, with Foci Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3609.71, up 0.33%, while the Shenzhen Component Index closed at 11289.41, up 0.64% [1] Top Gainers in Chinese Medicine Sector - Foci Pharmaceutical (002644) closed at 10.69, up 9.98% with a trading volume of 841,300 shares and a turnover of 876 million yuan [1] - Zhongsheng Pharmaceutical (002317) also rose by 9.98% to 19.73, with a trading volume of 1,168,400 shares and a turnover of 2.26 billion yuan [1] - Other notable gainers include: - Zhendong Pharmaceutical (300158) up 6.66% to 7.69 [1] - Huasen Pharmaceutical (002907) up 6.50% to 18.51 [1] - Kangjia Pharmaceutical (600557) up 5.61% to 16.58 [1] Top Losers in Chinese Medicine Sector - Qidi Pharmaceutical (000590) fell by 2.65% to 12.13, with a trading volume of 134,500 shares and a turnover of 163 million yuan [2] - Zhenbaodao (603567) decreased by 2.21% to 12.40, with a trading volume of 182,700 shares and a turnover of 227 million yuan [2] - Other notable losers include: - Yunnan Baiyao (000538) down 1.20% to 55.82 [2] - Kangmei Pharmaceutical (600518) down 0.94% to 2.10 [2] Capital Flow Analysis - The Chinese medicine sector saw a net inflow of 798 million yuan from institutional investors, while retail investors experienced a net outflow of 625 million yuan [2][3] - Notable net inflows from institutional investors include: - Zhongsheng Pharmaceutical (002317) with a net inflow of 308 million yuan [3] - Zhendong Pharmaceutical (300158) with a net inflow of 96.32 million yuan [3] - Conversely, significant net outflows from retail investors were observed in: - Zhongsheng Pharmaceutical (002317) with a net outflow of 98.88 million yuan [3] - Zhendong Pharmaceutical (300158) with a net outflow of 65.62 million yuan [3]

Investment Rating - The industry investment rating is "Overweight" [2] Core Viewpoints - The pharmaceutical sector is experiencing a divergence among its sub-industries, entering a phase of logical exploration [5] - The pharmaceutical index has outperformed the CSI 300 index, with a 1.9% increase this week, ranking 19th in terms of performance [17][19] - The highest valuation sub-industry is vaccines, with a PE (TTM) of 62X, while the lowest performing sub-industry is chemical preparations, which decreased by 2.02% [22] Summary by Sections Market Review - The pharmaceutical index rose by 1.9%, outperforming the CSI 300 index by 0.21 percentage points and the Shanghai Composite Index by 0.23 percentage points [17] - As of July 25, the PE (TTM) for the pharmaceutical industry is 28X, which is below the historical average of 33X [19] - Among 13 sub-industries, 11 saw increases, with medical research outsourcing leading at an 8.29% rise [22] Stock Performance - In the A-share market, 72.36% of the 474 pharmaceutical stocks increased in value this week [24] - The top ten performing stocks include Haitai Biological (+46.93%) and Zhendong Pharmaceutical (+42.89%) [25] - In the Hong Kong market, 66.67% of 114 stocks rose, with the top performer being MicroPort Medical (+28.86%) [31] Weekly Insights - The divergence in sub-industries is attributed to the focus on innovation and potential high-value products, with medical devices gaining market attention [5] - The National Healthcare Security Administration's guidance against price-only bidding has renewed interest in the medical device and IVD sectors [5] - The report maintains a bullish outlook on the pharmaceutical sector, emphasizing innovation in hard technology, including innovative drugs and devices [37] Investment Strategy - The investment strategy is divided into two main areas: innovative drug sector and other sectors [38] - Key recommendations include Zai Lab, BGI Genomics, and Junshi Biosciences, with a focus on oncology and innovative drug development [38] - Other sectors of interest include medical hard technology, medical consumption, and companies with significant overseas business [39][41]

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [2][40]. Core Insights - The pharmaceutical and biotechnology sector saw an overall increase of 1.90% from July 21 to July 25, 2025, ranking 19th among 31 industries in the Shenwan index, outperforming the CSI 300 index by 0.21 percentage points [4][12]. - The current PE valuation of the pharmaceutical and biotechnology sector is 30.67 times, which is at the historical median level, with a valuation premium of 140% compared to the CSI 300 index [4][18]. - The top three performing sub-sectors during the same period were medical services (6.73%), medical devices (4.43%), and pharmaceutical commerce (1.84%) [4][12]. Market Performance - In the year-to-date, the pharmaceutical and biotechnology sector has increased by 18.81%, ranking 3rd among 31 industries, and outperforming the CSI 300 index by 13.92 percentage points [4][13]. - The sub-sectors that achieved significant gains include chemical pharmaceuticals (34.25%), medical services (32.34%), and biological products (13.49%) [4][19]. Industry News - The National Healthcare Security Administration (NHSA) held two meetings to support the high-quality development of innovative drugs and medical devices, emphasizing the need for comprehensive value assessments for innovative products [5][34]. - The NHSA introduced new measures to empower innovation in drug and device pricing, aiming to support genuine innovation and improve the quality of healthcare in China [5][36]. Investment Recommendations - The report suggests focusing on high-quality stocks in the following segments: innovative drugs, CXO (Contract Research Organization), chain pharmacies, medical services, and second-class vaccines [5][37][38]. - Recommended stocks include Betta Pharmaceuticals, Teva Biopharmaceuticals, Kaili Medical, Haier Biomedical, Huaxia Eye Hospital, and Lao Bai Xing [5][38]. Stock Performance - During the last week, 337 stocks in the sector increased in value (71.10%), while 127 stocks decreased (26.79%). The top five gainers were Haitai Biological (46.93%), Zhendong Pharmaceutical (42.89%), Saili Medical (31.73%), Chenxin Pharmaceutical (30.75%), and Rendu Biological (27.82%) [4][27].

证券时报·数据宝统计，截至（7月28日）收盘，沪指报3597.94点，涨4.28点，涨幅为0.12%；深成指报 11217.58点，涨49.44点，涨幅为0.44%；创业板指报2362.60点，涨22.54点，涨幅为0.96%。个股方面， 今日87只A股换手率超过20%，其中C技源换手率达五成以上，半数筹码易主。（数据宝） （文章来源：证券时报网） 7月28日两市换手率居前个股一览 | 300158 | 振东制药 | 7.21 | 22.83 | 2.56 | | --- | --- | --- | --- | --- | | 301150 | 中一科技 | 26.21 | 22.71 | 9.80 | | 301076 | 新瀚新材 | 32.12 | 22.52 | 8.81 | | 300950 | 德固特 | 32.25 | 22.51 | 6.61 | | 603014 | 威高血净 | 39.92 | 22.50 | 3.74 | | 300588 | 熙菱信息 | 18.40 | 22.31 | -1.97 | | 300189 | 神农种业 | 4.84 | 21.91 | -2.02 | | ...